Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk

Dow Jones04-24

1454 ET - Vertex Pharmaceuticals seems not to have explored alternatives before its deal for kidney-disease treatment developer Alpine. Evercore ISI analysts Liisa Bayko and Jingming Chen say in a research note that Vertex revealed in a regulatory filing that it did not engage with the other major player in the B-cell modulator space, Vera Therapeutics. Vera and Alpine are both developing a form of treatment for IgA nephropathy, a common kidney disease with limited treatment options. The analysts say that they expect Vera to be one of the first companies to have its B-cell modulator approved, given its stage in development. Vera shares climb 3%, while Alpine is up 0.1% and Vertex rises 1.4%. (ben.glickman@wsj.com; @benglickman)

(END) Dow Jones Newswires

April 23, 2024 14:54 ET (18:54 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2429146713?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-24 02:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429146713","market":"other","top_or_hot":-1,"title":"Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1454 ET - Vertex Pharmaceuticals seems not to have explored alternatives before its deal for kidney-disease treatment developer Alpine. <a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI analysts Liisa Bayko and Jingming Chen say in a research note that Vertex revealed in a regulatory filing that it did not engage with the other major player in the B-cell modulator space, Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. Vera and Alpine are both developing a form of treatment for IgA nephropathy, a common kidney disease with limited treatment options. The analysts say that they expect Vera to be one of the first companies to have its B-cell modulator approved, given its stage in development. Vera shares climb 3%, while Alpine is up 0.1% and Vertex rises 1.4%. (ben.glickman@wsj.com; @benglickman) \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 23, 2024 14:54 ET (18:54 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVertex Doesn't Seem To Have Engaged With Other Players Before Alpine Deal -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-24 02:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1454 ET - Vertex Pharmaceuticals seems not to have explored alternatives before its deal for kidney-disease treatment developer Alpine. Evercore ISI analysts Liisa Bayko and Jingming Chen say in a ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALPN","symbol_name":"Alpine Immune Sciences Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2429146713","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429146713","pubTimestamp":1713898440,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1454 ET - Vertex Pharmaceuticals seems not to have explored alternatives before its deal for kidney-disease treatment developer Alpine. Evercore ISI analysts Liisa Bayko and Jingming Chen say in a research note that Vertex revealed in a regulatory filing that it did not engage with the other major player in the B-cell modulator space, Vera Therapeutics. Vera and Alpine are both developing a form of treatment for IgA nephropathy, a common kidney disease with limited treatment options. The analysts say that they expect Vera to be one of the first companies to have its B-cell modulator approved, given its stage in development. Vera shares climb 3%, while Alpine is up 0.1% and Vertex rises 1.4%. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALPN":"Alpine Immune Sciences Inc.","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","VERA":"Vera Therapeutics, Inc.","BK4539":"次新股","BK4023":"应用软件","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BK4585":"ETF&股票定投概念","BK4567":"ESG概念","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4139":"生物科技","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0079474960.USD":"联博美国增长基金A","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","VERX":"Vertex, Inc.","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","VTNR":"顶点能源","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","BK4588":"碎股","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","VRTX":"福泰制药","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4138":"石油与天然气的炼制和营销"},"translate_title":"在Alpine交易市场谈判之前，Vertex似乎没有与其他参与者合作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTNR":1,"VRTX":1,"VERX":1,"ALPN":0.9,"VERA":0.9},"content_text":"1454 ET - Vertex Pharmaceuticals seems not to have explored alternatives before its deal for kidney-disease treatment developer Alpine. Evercore ISI analysts Liisa Bayko and Jingming Chen say in a research note that Vertex revealed in a regulatory filing that it did not engage with the other major player in the B-cell modulator space, Vera Therapeutics. Vera and Alpine are both developing a form of treatment for IgA nephropathy, a common kidney disease with limited treatment options. The analysts say that they expect Vera to be one of the first companies to have its B-cell modulator approved, given its stage in development. Vera shares climb 3%, while Alpine is up 0.1% and Vertex rises 1.4%. (ben.glickman@wsj.com; @benglickman) \n\n\n  (END) Dow Jones Newswires\n\n\n  April 23, 2024 14:54 ET (18:54 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429146713"}